Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

New Commercial Opportunities for Liposomes Emerge

Liposomes were once touted as membranous “magic bullets” that would be modern, all-purpose carriers for drugs, enzymes, and genetic material. While this overoptimistic appraisal led to disappointment, researchers have found new applications for liposome technology and new ways to engineer liposomes to perform specific functions. These applications have attracted investment in several liposome-based companies and in research programs at multinational pharmaceutical houses. A number of liposome-based diagnostic, therapeutic, and veterinary products will soon face the test of the marketplace. Meanwhile, promising research results indicate that highly focused R&D programs could lead to a new generation of immune stimulants and anti-cancer agents based upon the liposome's ability to stimulate cellular processes.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wilson, T., Cave, L. New Commercial Opportunities for Liposomes Emerge. Nat Biotechnol 1, 148–154 (1983). https://doi.org/10.1038/nbt0483-148

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0483-148

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing